237 related articles for article (PubMed ID: 28856610)
1. Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients.
Leo M; Sabini E; Ionni I; Sframeli A; Mazzi B; Menconi F; Molinaro E; Bianchi F; Brozzi F; Santini P; Elisei R; Nardi M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2018 Mar; 41(3):357-361. PubMed ID: 28856610
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effect of low-dose radioiodine ablation for Graves' orbitopathy: results of a retrospective study.
Lanzolla G; Menconi F; Nicolì F; Posarelli C; Maglionico MN; Figus M; Nardi M; Marcocci C; Marinò M
J Endocrinol Invest; 2021 Dec; 44(12):2575-2579. PubMed ID: 33844165
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe graves' orbitopathy (GO): a prospective, randomized, single-blind clinical trial.
Moleti M; Violi MA; Montanini D; Trombetta C; Di Bella B; Sturniolo G; Presti S; Alibrandi A; Campennì A; Baldari S; Trimarchi F; Vermiglio F
J Clin Endocrinol Metab; 2014 May; 99(5):1783-9. PubMed ID: 24432992
[TBL] [Abstract][Full Text] [Related]
4. Total thyroid ablation in Graves' orbitopathy.
Menconi F; Leo M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2015 Aug; 38(8):809-15. PubMed ID: 25740065
[TBL] [Abstract][Full Text] [Related]
5. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids.
Menconi F; Marinò M; Pinchera A; Rocchi R; Mazzi B; Nardi M; Bartalena L; Marcocci C
J Clin Endocrinol Metab; 2007 May; 92(5):1653-8. PubMed ID: 17299076
[TBL] [Abstract][Full Text] [Related]
6. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
7. Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study.
Lanzolla G; Ricci D; Nicolì F; Sabini E; Sframeli A; Brancatella A; Mantuano M; Dottore GR; Bucci I; Figus M; Nardi M; Latrofa F; Marcocci C; Marinò M
J Endocrinol Invest; 2020 Dec; 43(12):1759-1768. PubMed ID: 32583374
[TBL] [Abstract][Full Text] [Related]
8. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.
De Bellis A; Conzo G; Cennamo G; Pane E; Bellastella G; Colella C; Iacovo AD; Paglionico VA; Sinisi AA; Wall JR; Bizzarro A; Bellastella A
Endocrine; 2012 Apr; 41(2):320-6. PubMed ID: 22169963
[TBL] [Abstract][Full Text] [Related]
9. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A
J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846
[TBL] [Abstract][Full Text] [Related]
10. Serum thyroglobulin is associated with orbitopathy in Graves' disease.
Khamisi S; Lundqvist M; Emadi P; Almby K; Ljunggren Ö; Karlsson FA
J Endocrinol Invest; 2021 Sep; 44(9):1905-1911. PubMed ID: 33515213
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone.
Berg G; Lindstedt G; Suurküla M; Jansson S
J Endocrinol Invest; 2002 Jan; 25(1):44-52. PubMed ID: 11883865
[TBL] [Abstract][Full Text] [Related]
12. Is Recombinant Human TSH a Trigger for Graves' Orbitopathy?
Daumerie C; Boschi A; Perros P
Eur Thyroid J; 2012 Jul; 1(2):105-9. PubMed ID: 24783004
[TBL] [Abstract][Full Text] [Related]
13. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study.
Vannucchi G; Covelli D; Campi I; Currò N; Dazzi D; Rodari M; Pepe G; Chiti A; Guastella C; Lazzaroni E; Salvi M
Thyroid; 2019 Dec; 29(12):1828-1833. PubMed ID: 31860407
[No Abstract] [Full Text] [Related]
14. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
Giovanella L; Ceriani L; Ghelfo A; Keller F; Sacchi A; Maffioli M; Spriano G
Clin Chem Lab Med; 2006; 44(5):648-52. PubMed ID: 16681439
[TBL] [Abstract][Full Text] [Related]
15. Natural history of graves' orbitopathy after treatment.
Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
[TBL] [Abstract][Full Text] [Related]
16. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
17. Improving treatment outcomes for Graves' disease patients with inactive forms of Graves' orbitopathy through an increased dose of radioiodine therapy.
Gosmann J; Willms D; Bell E; Schreckenberger M; Willms A
Nuklearmedizin; 2020 Jun; 59(3):260-268. PubMed ID: 32403138
[TBL] [Abstract][Full Text] [Related]
18. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
19. Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of graves' ophthalmopathy.
Moleti M; Mattina F; Salamone I; Violi MA; Nucera C; Baldari S; Lo Schiavo MG; Regalbuto C; Trimarchi F; Vermiglio F
Thyroid; 2003 Jul; 13(7):653-8. PubMed ID: 12964971
[TBL] [Abstract][Full Text] [Related]
20. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]